Yueh Wang - Arlington Heights IL, US John Lopez - Gurnee IL, US Ayyappan Nair - Des Plaines IL, US Zhengyu Huang - Buffalo Grove IL, US
Assignee:
Valent BioSciences Corporation - Libertyville IL
International Classification:
A01N 25/00 A01N 65/00 A01N 43/40
US Classification:
5041161, 504189, 504244
Abstract:
The invention relates to low VOC plant growth regulator compositions comprising less than about 25% of volatile organic compounds (VOCs). The compositions comprise forchlorfenuron (CPPU). Also provided are methods of using the compositions.
Low Voc And Stable Plant Growth Regulator Liquid And Granule Compositions
Yueh Wang - Arlington Heights IL, US John Lopez - Gurnee IL, US Ayyappan Nair - Des Plaines IL, US Zhengyu Huang - Buffalo Grove IL, US
International Classification:
A01N 47/36 A01N 43/90 A01P 21/00
US Classification:
504210, 504241
Abstract:
The invention relates to low VOC plant growth regulator compositions comprising less than about 25% of volatile organic compounds (VOCs). The compositions preferably comprise 6-benzyladenine (6-BA) or forchlorfenuron (CPPU). Also provided are methods of using the compositions.
Terry A. Benson - Spring Grove IL, US Samun Dahod - Bristol WI, US Ashish Harihar Dave - Wheeling IL, US Ayyappan Nair - Des Plaines IL, US Regina Adams - Lake Villa IL, US
International Classification:
A01N 63/00 C12N 1/20 A01P 15/00
US Classification:
424 93461, 4352525
Abstract:
A novel bacterial strain of , VBTS 2528, is described. This strain comprises genes encoding Cry1Ac, Cry 1Ca, and Cry2Aa endotoxin proteins. The invention further relates to an insecticidal composition comprising a mixture of VBTS 2528 and to methods for controlling insect pests utilizing VBTS 2528.
- Libertyville IL, US Benjamin A. Belkind - Wilmette IL, US Ayyappan Nair - Des Plaines IL, US Gregory D. Venburg - Deerfield IL, US Robert Fassel - Naches WA, US Yong-Ki Kim - Yakima WA, US
The present invention generally relates to concentrated natamycin suspension formulations for inhibition of fungal growth. Specifically, the present invention relates to stable suspension concentrate formulations comprising from about 25% to about 48% w/w natamycin, from about 0.1% to about 10% w/w of an anionic surfactant selected from the group consisting of polyelectrolyte polymers, modified styrene acrylic polymers, dioctyl sodium sulfosuccinates, sodium salts of naphthalene sulfonates, and combinations thereof, and water. The formulations of the present invention contain natamycin as particles which are on average less than 11 microns in diameter and the formulations have a viscosity of less than 1400 centipoise at 21 degrees Celsius.